The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase III randomized trial of eribulin (E) with gemcitabine vs standard of care (SOC) for patients (pts) with metastatic urothelial carcinoma (mUC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937—Updated design.
 
Sarmad Sadeghi
Employment - BeiGene (I)
Stock and Other Ownership Interests - BeiGene (I)
 
Samuel Callis
No Relationships to Disclose
 
Primo Lara
Consulting or Advisory Role - Genmab
Research Funding - AstraZeneca (Inst)
 
Stephanie Berg
Honoraria - Aptitude Health; MJH Life Sciences
Consulting or Advisory Role - Bristol Meyers Squibb; Eisai; Exelixis; Exelixis; Genzyme; Myovant Sciences; Pfizer; Seattle Genetics/Astellas
 
Jason Brown
Honoraria - AstraZeneca
Consulting or Advisory Role - EMD Serono; Johnson & Johnson/Janssen; Pfizer
Speakers' Bureau - EMD Serono
Research Funding - Bicycle Therapeutics (Inst); Merck (Inst); Novita Pharmaceuticals (Inst); Pfizer (Inst); Seagen (Inst)
 
Rick Bangs
Honoraria - Gilead Sciences
Consulting or Advisory Role - Gilead Sciences; Nonagen Bioscience
Travel, Accommodations, Expenses - Gilead Sciences
Other Relationship - Bladder Cancer Advocacy Network; National Cancer Institute; SWOG; SWOG; SWOG
(OPTIONAL) Uncompensated Relationships - Genentech; Gilead Sciences
 
Darrell Nakagawa
Leadership - Bladder Cancer Advocacy Network
Honoraria - Tyra Biosciences
 
Siamak Daneshmand
No Relationships to Disclose
 
Ian Thompson
Employment - CHRISTUS Health; CHRISTUS Health
Leadership - H-E-B (grocery store chain)
Consulting or Advisory Role - Magforce
Research Funding - MagForce
Patents, Royalties, Other Intellectual Property - I have several patents with colleagues involving novel biomarkers for cancer and two devices for sexual dysfunction and urinary incontinence. No revenues at this time and our University IP office is working with industry to determine if these can be comme
 
Thomas Flaig
Leadership - Aurora Oncology; CPC - Clinical Research and Community Health; University of Colorado/UC Health
Stock and Other Ownership Interests - Aurora Oncology
Consulting or Advisory Role - Janssen Oncology; Seagen
Research Funding - Agensys; Aragon Pharmaceuticals; Astellas Pharma; astrazeneca/MedImmune; Bavarian Nordic; Bristol-Myers Squibb; Criterium; Dendreon; Exelixis; GTx; Janssen Oncology; La Roche-Posay; Lilly; Medivation; Merck; Myovant Sciences; Novartis; Pfizer; Roche/Genentech; Sanofi; Seagen; Seagen; Sotio; Tokai Pharmaceuticals
Patents, Royalties, Other Intellectual Property - The University of Colorado has filed 2 patents in which I am an inventor. These are related to early-stage bladder cancer treatment and detection. Neither is commercialized or in active clinical development right now (e.g. neither are in clinical trials).
 
Daniel Petrylak
Consulting or Advisory Role - Advanced Accelerator Applications; Amgen; Astellas Pharma; AstraZeneca; Bayer; Bicycle Therapeutics; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Exelixis; Gilead Sciences; Incyte; Ipsen; Janssen; Lilly; Mirati Therapeutics; Monopteros Therapeutics; Pfizer; Pharmacyclics; Regeneron; Roche; Seagen; Urogen pharma
Research Funding - Advanced Accelerator Applications (Inst); Agensys (Inst); Astellas Medivation (Inst); AstraZeneca (Inst); Bayer (Inst); BioXCel therapeutics (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Eisai (Inst); Endocyte (Inst); Genentech (Inst); Gilead Sciences (Inst); Innocrin Pharma (Inst); Lilly (Inst); MedImmune (Inst); Medivation (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Progenics (Inst); Replimune (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst)
Expert Testimony - Celgene; sanofi
 
Seth Lerner
Stock and Other Ownership Interests - Aura Biosciences; C2i genomics
Honoraria - Grand Rounds in Urology; UroToday
Consulting or Advisory Role - AstraZeneca; Aura Biosciences; Bristol-Myers Squibb Foundation/Janssen; C2i Genomics; Ferring; Gilead Sciences; ImmunityBio; Incyte; Pfizer/EMD Serono; Protara Therapeutics; Stimit; Urogen pharma; Vaxiion; Verity Pharmaceuticals
Research Funding - Aura Biosciences; Endo Pharmaceuticals; FKD Therapies; Japan BCG Laboratory; QED Therapeutics; Roche/Genentech; SURGE Therapeutics; Vaxiion; Viventia Biotech
Patents, Royalties, Other Intellectual Property - TCGA expression subtype singel patient classifier
Other Relationship - Bladder Cancer Journal; UpToDate